BE1031219B1 - Composition, cellules immunitaires la comprenant et utilisation de ces dernières - Google Patents

Composition, cellules immunitaires la comprenant et utilisation de ces dernières

Info

Publication number
BE1031219B1
BE1031219B1 BE20226101A BE202206101A BE1031219B1 BE 1031219 B1 BE1031219 B1 BE 1031219B1 BE 20226101 A BE20226101 A BE 20226101A BE 202206101 A BE202206101 A BE 202206101A BE 1031219 B1 BE1031219 B1 BE 1031219B1
Authority
BE
Belgium
Prior art keywords
composition
transposase
immune cells
target
nucleic acid
Prior art date
Application number
BE20226101A
Other languages
English (en)
Other versions
BE1031219A1 (fr
Inventor
François Cherbonneau
Prunevieille Aurore Cherbonneau
Original Assignee
Quidditas Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quidditas Sa filed Critical Quidditas Sa
Priority to BE20226101A priority Critical patent/BE1031219B1/fr
Priority to KR1020257024824A priority patent/KR20250127145A/ko
Priority to IL321711A priority patent/IL321711A/en
Priority to JP2025538430A priority patent/JP2026501380A/ja
Priority to EP23844100.0A priority patent/EP4623080A1/fr
Priority to AU2023416551A priority patent/AU2023416551A1/en
Priority to CN202380089444.4A priority patent/CN120569472A/zh
Priority to PCT/EP2023/087873 priority patent/WO2024141570A1/fr
Publication of BE1031219A1 publication Critical patent/BE1031219A1/fr
Application granted granted Critical
Publication of BE1031219B1 publication Critical patent/BE1031219B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L’invention concerne une composition comprenant - une première molécule d’acides nucléiques simple brin comprenant une région complémentaire d’une cible et des sites de reconnaissance d’une transposase, - une deuxième molécule d’acides nucléiques simple brin comprenant une région complémentaire d’une cible et des sites de reconnaissance d’une transposase, et - une troisième molécule simple brin comprenant une séquence codant du CD3ζ du TCR, et des sites de liaison à une transposase.
BE20226101A 2022-12-28 2022-12-28 Composition, cellules immunitaires la comprenant et utilisation de ces dernières BE1031219B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
BE20226101A BE1031219B1 (fr) 2022-12-28 2022-12-28 Composition, cellules immunitaires la comprenant et utilisation de ces dernières
KR1020257024824A KR20250127145A (ko) 2022-12-28 2023-12-28 조성물, 이를 포함하는 면역세포 및 상기 면역세포의 용도
IL321711A IL321711A (en) 2022-12-28 2023-12-28 Composition, immune cells comprising same, and use of said immune cells
JP2025538430A JP2026501380A (ja) 2022-12-28 2023-12-28 組成物、それを含む免疫細胞、及びその免疫細胞の使用
EP23844100.0A EP4623080A1 (fr) 2022-12-28 2023-12-28 Composition, cellules immunitaires la comprenant et utilisation de ces dernières
AU2023416551A AU2023416551A1 (en) 2022-12-28 2023-12-28 Composition, immune cells comprising same, and use of said immune cells
CN202380089444.4A CN120569472A (zh) 2022-12-28 2023-12-28 组合物、包含该组合物的免疫细胞和所述免疫细胞的用途
PCT/EP2023/087873 WO2024141570A1 (fr) 2022-12-28 2023-12-28 Composition, cellules immunitaires la comprenant et utilisation de ces dernières

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BE20226101A BE1031219B1 (fr) 2022-12-28 2022-12-28 Composition, cellules immunitaires la comprenant et utilisation de ces dernières

Publications (2)

Publication Number Publication Date
BE1031219A1 BE1031219A1 (fr) 2024-07-23
BE1031219B1 true BE1031219B1 (fr) 2024-07-29

Family

ID=85157004

Family Applications (1)

Application Number Title Priority Date Filing Date
BE20226101A BE1031219B1 (fr) 2022-12-28 2022-12-28 Composition, cellules immunitaires la comprenant et utilisation de ces dernières

Country Status (8)

Country Link
EP (1) EP4623080A1 (fr)
JP (1) JP2026501380A (fr)
KR (1) KR20250127145A (fr)
CN (1) CN120569472A (fr)
AU (1) AU2023416551A1 (fr)
BE (1) BE1031219B1 (fr)
IL (1) IL321711A (fr)
WO (1) WO2024141570A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119306841B (zh) * 2024-12-13 2025-03-07 北京细胞治疗集团有限公司 一种pb转座酶单克隆抗体及其检测试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046636A1 (fr) * 2017-08-30 2019-03-07 The Broad Institute, Inc. Édition basée sur crispr de type hdr à double sélection
WO2021061832A1 (fr) * 2019-09-23 2021-04-01 Regents Of The University Of Minnesota Cellules immunitaires génétiquement éditées et procédés de traitement

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4628587A3 (fr) 2016-04-15 2026-02-25 Memorial Sloan Kettering Cancer Center Compositions de lymphocytes t transgéniques et de lymphocytes t à récepteur antigénique chimérique et procédés associés
US20220273715A1 (en) * 2019-07-25 2022-09-01 Precision Biosciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019046636A1 (fr) * 2017-08-30 2019-03-07 The Broad Institute, Inc. Édition basée sur crispr de type hdr à double sélection
WO2021061832A1 (fr) * 2019-09-23 2021-04-01 Regents Of The University Of Minnesota Cellules immunitaires génétiquement éditées et procédés de traitement

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E. L. ARONOVICH ET AL: "The Sleeping Beauty transposon system: a non-viral vector for gene therapy", HUMAN MOLECULAR GENETICS, vol. 20, no. R1, 15 April 2011 (2011-04-15), pages R14 - R20, XP055177523, ISSN: 0964-6906, DOI: 10.1093/hmg/ddr140 *
KLOMPE SANNE E ET AL: "Transposon-encoded CRISPR-Cas systems direct RNA-guided DNA integration", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 571, no. 7764, 12 June 2019 (2019-06-12), pages 219 - 225, XP036831898, ISSN: 0028-0836, [retrieved on 20190612], DOI: 10.1038/S41586-019-1323-Z *
MIYAMOTO TATSUO ET AL: "Updated summary of genome editing technology in human cultured cells linked to human genetics studies", JOURNAL OF HUMAN GENETICS, SPRINGER SINGAPORE, SINGAPORE, vol. 63, no. 2, 11 October 2017 (2017-10-11), pages 133 - 143, XP036428428, ISSN: 1434-5161, [retrieved on 20171011], DOI: 10.1038/S10038-017-0349-Z *
MORIARITY BRANDEN S. ET AL: "Modular assembly of transposon integratable multigene vectors using RecWay assembly", NUCLEIC ACIDS RESEARCH, vol. 41, no. 8, 1 April 2013 (2013-04-01), GB, pages e92 - e92, XP055919256, ISSN: 0305-1048, Retrieved from the Internet <URL:https://watermark.silverchair.com/gkt115.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAtAwggLMBgkqhkiG9w0BBwagggK9MIICuQIBADCCArIGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMghSykix3GnbnsRg3AgEQgIICgxhhEjk4CGu901FL7BLEZFR874_GYKchEUcU6fiEKuYmo8NIDpvKm6FPsGcoI_TSV_hwU4FIq81bnEeIxMEwHKDsOGEI0> DOI: 10.1093/nar/gkt115 *

Also Published As

Publication number Publication date
JP2026501380A (ja) 2026-01-14
IL321711A (en) 2025-08-01
EP4623080A1 (fr) 2025-10-01
KR20250127145A (ko) 2025-08-26
AU2023416551A1 (en) 2025-07-17
WO2024141570A1 (fr) 2024-07-04
CN120569472A (zh) 2025-08-29
BE1031219A1 (fr) 2024-07-23

Similar Documents

Publication Publication Date Title
Hennig et al. Large-scale low-cost NGS library preparation using a robust Tn5 purification and tagmentation protocol
Schaper et al. Interaction of the initiator protein DnaA of Escherichia coli with its DNA target
Lee et al. A previously unidentified host protein protects retroviral DNA from autointegration
Koch et al. A proteogenomics approach integrating proteomics and ribosome profiling increases the efficiency of protein identification and enables the discovery of alternative translation start sites
Villanueva-Canas et al. New genes and functional innovation in mammals
Pandey et al. Identification of a novel immunoreceptor tyrosine-based activation motif-containing molecule, STAM2, by mass spectrometry and its involvement in growth factor and cytokine receptor signaling pathways
Pronobis et al. The Miraprep: A protocol that uses a Miniprep kit and provides Maxiprep yields
Dickinson et al. Inhibition of Ets-1 DNA binding and ternary complex formation between Ets-1, NF-κB, and DNA by a designed DNA-binding ligand
Kim et al. Two‐promoter vector is highly efficient for overproduction of protein complexes
Bonchuk et al. BTB domains: a structural view of evolution, multimerization, and protein–protein interactions
Khan et al. Extracellular identification of a processed type II ComR/ComS pheromone of Streptococcus mutans
Lu et al. Gene target specificity of the Super Elongation Complex (SEC) family: how HIV-1 Tat employs selected SEC members to activate viral transcription
Liu et al. Intrinsic and extrinsic connections of Tet3 dioxygenase with CXXC zinc finger modules
Gayet et al. Autocatalytic base editing for RNA-responsive translational control
Dyhr-Mikkelsen Inefficient Spliceosome Assembly and Abnormal Branch Site Selection in Splicing of an HIV-1 Transcript in Vitro (∗)
BE1031219B1 (fr) Composition, cellules immunitaires la comprenant et utilisation de ces dernières
IL308426B1 (en) Adenosine nucleobase editors and uses thereof
Morales et al. Development of a toolbox to dissect host-endosymbiont interactions and protein trafficking in the trypanosomatid Angomonas deanei
Gopalakrishna et al. C6orf203 is an RNA-binding protein involved in mitochondrial protein synthesis
Lin et al. Protein trans-splicing of multiple atypical split inteins engineered from natural inteins
Wenck et al. Archaeal transcription
JOP20230008A1 (ar) أجسام مضادة للبيتاسيلولين، شظايا منها، وجزيئات ارتباط متعددة الخصوصية
Suckow et al. Replacement of invariant bzip residuces within the basic region of the yeast transcriptional activator GCN4 can change its DNA binding specificity
Bhattacharya et al. Structural basis of the interaction between SETD2 methyltransferase and hnRNP L paralogs for governing co-transcriptional splicing
Cain et al. Prediction of cooperative homeodomain DNA binding sites from high-throughput-SELEX data

Legal Events

Date Code Title Description
FG Patent granted

Effective date: 20240729